
Sales of Darzalex, which is a bone marrow cancer drug, are significantly exceeding expectations, Genmab reports in a stock exchange notification.
The company has therefore decided to upgrade its financial guidance for the full year to an operating result of DKK 2.3-3.2bn (USD 360-500m) and a revenue of DKK 7.9-8.5bn (USD 1.2-1.3bn). Previously, Genmab had expected an operating result of DKK 1.5-2.4bn (USD 230-370m) and a revenue of DKK 7.3-7.9bn (USD 1.1-1.2bn).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app